OBJECTIVES: We describe the antimicrobial activity against Pseudomonas aeruginosa of the de novo-derived antimicrobial peptide WLBU2 in an animal model of infection. METHODS: For this study, an intravenous (iv) model of P. aeruginosa infection was established. The minimum lethal murine dose of P. aeruginosa strain PA01 was determined to be 3 x 10(7) cfu when bacteria were administered iv. Increasing concentrations of WLBU2 were instilled either prior to or following PA01 septic exposure. RESULTS: For the mice given peptide post-bacterial infection, in the 1 mg/kg group, nine of nine animals died because of Pseudomonas sepsis; in the 3 mg/kg group, only one of nine succumbed to infection and in the 4 mg/kg group, all mice were protected (P < 0.0001). Similar results were obtained when WLBU2 was given 1 h prior to Pseudomonas infection. CONCLUSIONS: Although the therapeutic window in this model is narrow, the results nonetheless provide encouraging evidence for WLBU2 as a potential prophylactic or treatment of bacterial infection.
OBJECTIVES: We describe the antimicrobial activity against Pseudomonas aeruginosa of the de novo-derived antimicrobial peptide WLBU2 in an animal model of infection. METHODS: For this study, an intravenous (iv) model of P. aeruginosa infection was established. The minimum lethal murine dose of P. aeruginosa strain PA01 was determined to be 3 x 10(7) cfu when bacteria were administered iv. Increasing concentrations of WLBU2 were instilled either prior to or following PA01 septic exposure. RESULTS: For the mice given peptide post-bacterial infection, in the 1 mg/kg group, nine of nine animals died because of Pseudomonassepsis; in the 3 mg/kg group, only one of nine succumbed to infection and in the 4 mg/kg group, all mice were protected (P < 0.0001). Similar results were obtained when WLBU2 was given 1 h prior to Pseudomonasinfection. CONCLUSIONS: Although the therapeutic window in this model is narrow, the results nonetheless provide encouraging evidence for WLBU2 as a potential prophylactic or treatment of bacterial infection.
Authors: Shruti M Phadke; Berthony Deslouches; Sara E Hileman; Ronald C Montelaro; Harold C Wiesenfeld; Timothy A Mietzner Journal: J Nutr Date: 2005-05 Impact factor: 4.798
Authors: Berthony Deslouches; Shruti M Phadke; Vanja Lazarevic; Michael Cascio; Kazi Islam; Ronald C Montelaro; Timothy A Mietzner Journal: Antimicrob Agents Chemother Date: 2005-01 Impact factor: 5.191
Authors: Shruti M Phadke; Kazi Islam; Berthony Deslouches; Sunil A Kapoor; Donna Beer Stolz; Simon C Watkins; Ronald C Montelaro; Joseph M Pilewski; Timothy A Mietzner Journal: Peptides Date: 2003-08 Impact factor: 3.750
Authors: Xiangming Wu; Matthew P Ryder; Joseph McGuire; Joshua L Snider; Karl F Schilke Journal: Colloids Surf B Biointerfaces Date: 2015-04-14 Impact factor: 5.268
Authors: Frank Heinrich; Aria Salyapongse; Akari Kumagai; Fernando G Dupuy; Karpur Shukla; Anja Penk; Daniel Huster; Robert K Ernst; Anna Pavlova; James C Gumbart; Berthony Deslouches; Y Peter Di; Stephanie Tristram-Nagle Journal: Chemistry Date: 2020-04-28 Impact factor: 5.236
Authors: Berthony Deslouches; Jonathan D Steckbeck; Jodi K Craigo; Yohei Doi; Jane L Burns; Ronald C Montelaro Journal: Antimicrob Agents Chemother Date: 2014-11-24 Impact factor: 5.191
Authors: M C Skinner; A O Kiselev; C E Isaacs; T A Mietzner; R C Montelaro; M F Lampe Journal: Antimicrob Agents Chemother Date: 2009-12-14 Impact factor: 5.191
Authors: Akari Kumagai; Fernando G Dupuy; Zoran Arsov; Yasmene Elhady; Diamond Moody; Robert K Ernst; Berthony Deslouches; Ronald C Montelaro; Y Peter Di; Stephanie Tristram-Nagle Journal: Soft Matter Date: 2019-02-20 Impact factor: 3.679
Authors: Leonard T Nguyen; Johnny K Chau; Nicole A Perry; Leonie de Boer; Sebastian A J Zaat; Hans J Vogel Journal: PLoS One Date: 2010-09-10 Impact factor: 3.240